Liver International

We publish high-quality original research in Hepatology / Co-EICs @lucavalenti75 @AghemoAlessio @Alexfornergon / IF=6.0 / RT ≠ endorsment

[Jonathan G. Stine, MD MSc, FACP @JonathanStineMD]

🔥 🆙 to publish this work with @HD3vedi and team regarding the importance of #exercise across all types and stages of steatotic liver disease!

Check it out here:

https://t.co/EJ3rUBdeJC

[Thomas Reiberger @ReibergerThomas]

You can continue #Anticoagulation when you perform #endoscopicbandligation #ELB for #varices

When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis

@LiverInt
🔗https://t.co/JzIVTJJ4Mm

[Yujun_Wong @Yujun__Wong]

Anticoagulation did 🚫increase the risk of bleeding

With/without anticoagulation during EVL, we found a similar risk of:
1) Overall bleeding
2) Severe bleeding
3) Post-banding ulcer bleeding

#Livertwitter 👉https://t.co/gWNPZK58in…

[Brendan Harney @BrendanLHarney]

Very excited to have the final paper from my #PhD published #OpenAccess in @LiverInt

While #HCV DAA treatment is highly effective, it is important to understand why a small minority are not cured. We aimed to do this with data from 🇦🇺🇨🇦🇫🇷🇳🇱🇪🇸🇨🇭
https://t.co/qBUoZ1gVni

[Juntendo University @juntendo_univ]

In this @LiverInt study, researchers from #Japan shed light on how #MICOS defects impair #mitochondrial function in #MitochondrialDNAdepletionSyndrome, opening new avenues for genetic testing and therapies.

Learn more: https://t.co/cXt8X15vc1

[Liver International @LiverInt]

2/2
💡 The clinical impact? Using genetics to interpret LBTs may reduce false positives/negatives, optimize resources, and improve diagnostics

further validation in diverse populations is needed! 🌍🩺

#livertwitter

[Liver International @LiverInt]

1/2
⬆️ liver tests may not always indicate a higher risk of serious liver disease

Genetic variants influencing common liver test results (like GGT & bilirubin) don't always correlate with higher cirrhosis risk 🤔

🔓https://t.co/BbKxvgLqxF

#livertwitter

[Josh Bilson @J_Bilson_]

The number and type of metabolic syndrome traits have important impacts on the risk of CKD and incident ESRD in people with MASLD.
@EScorletti, @Alessan95336031, @LiverInt
Read our recent work here:
https://t.co/eV0gBxEJQF

[Ezequiel Mauro @ezemauro_ok]

🚨 Out now in @LiverInt:
New scenarios in LT for HCC
👥 Led by a great international team in the field.
@Alexfornergon @goncrespo1 @A_DAlessioMD @DJPinato @ColmeneroJordi @liverunitclinic @hospitalclinic @idibaps @BCLC_group @CHBPaulBrousse @HUReinaSofia
https://t.co/tIPAsYHT7n

[Nkengeh N. Tazinkeng (Davy), MD @NkengehNTD]

G-CSF is not inferior to corticosteroids in improving 90-day overall survival and 6-months transplant free survival in patients with severe alcohol-associated hepatitis.

Singh et Al @LiverInt

https://t.co/jYQn4fd9nf

#livertwitter #GITwitter

[Angelo Armandi, MD, PhD @AngeloArmandi]

Our latest review on the impact of #PNPLA3 variants on clinical outcomes in #MASLD is out in @LiverInt open access @salvatore_petta @lucavalenti75 @stefano_romeo76

https://t.co/cZM8XXEeps

[Zayed Rashid, MD @ZRashidMD]

🚨 New Research Alert! 🚨
Latest paper in @LiverInt by the @OhioStateSurg TEAM explores the impact of #GLP1RA on adverse liver outcomes among patients with #Alcohol associated #liver disease and type 2 #diabetes
Link 👉 https://t.co/m2L7jsvdpr

💡Key finding
GLP-1RA = ⬇️ incidence of adverse liver outcome particularly #hepatic #decompensation

@timpawlik #MedTwitter @ProjectImg

[Adriana Palom @adrianapalom24]

🔴Our work about the burden of hepatitis D in the context of reflex testing has received over 500 views since publication!
📃Read it here https://t.co/wrn7Pa9XuC #ViewsMilestone

@Mariabutif @AEEHLiver @LiverInt

[Laura Turco @Laura_Turco83]

What a news from @LiverInt! 🥳
Our review on CARVEDILOL IN PORTAL HYPERTENSION has received over 20,000 views since publication! 🥰
@ReibergerThomas @VincenzoLaMura @GiovanniVitale
🔽 https://t.co/MWOL0wJGkb #ViewsMilestone

[Juan Turnes @jturnesv]

Necesidades no cubiertas en pacientes con hepatitis autoinmune (y son unas cuantas):

👉 Solo el 62% de los pacientes logran respuesta completa tras 1 año de tto
⚠️ Apenas el 27% lo consigue sin esteroides
🔄 30% de los pacientes cambian de tratamiento por intolerancia o no respuesta
📉 Heterogeneidad extrema en los tratamientos entre centros
❌ Necesitamos más alternativas terapéuticas efectivas y seguras

🔓 https://t.co/9pKqq6NgaX en @LiverInt

Detalle relevante: tampoco debería sorprendernos, el tto estándar tiene 50 años!

#livertwitter #HAI

[Thomas Reiberger @ReibergerThomas]

🚨#livertwitter
#Hepatitis #HCV #Elimination

🇦🇹 Austrian #HCV Elimination Project
supported @GileadSciences

5695 #HCV patients screened
397 started on #Antivirals #DAA
326 #HCV patients cured #SVR
✅ #HepC Cure 😇 Survival Benefit

📕@LiverInt
🔗https://t.co/mBPSTF58aR

[Arun J. Sanyal @ArunJSanyalVCU]

New insights into liver fibrosis in @LiverInt! SHG/TPEF microscopy with #AI offers precise assessment of #fibrosis in MASH F3 patients, revealing changes even when standard scoring shows 'no change.' #livertwitter @DavidKleiner12 https://t.co/GO2PLIHI24

[Elliot Tapper @ebtapper]

“The Liver would be better”

The story behind Neruda’s ode to the liver by @MarcoArreseMD in @LiverInt

https://t.co/vTA8MuXkWM

[Esli Medina @jemedinaMD]

Just recently published at @LiverInt , our work on waitlist outcomes and post-transplant outcomes in MASLD/AIH.
We found better waitlist outcomes on MASLD/AIH compared to MASLD and AIH. No differences on post-LT outcomes.@BonderAlan @HD3vedi @AnaMarencoMD
https://t.co/XRTMk2fhJX

[Liver International @LiverInt]

2/2
‼️ Despite its efficacy, 31% of patients experienced relapses, successfully managed with additional Rituximab cycles

While promising, prospective studies are needed to validate these findings in advanced #AIH

#livertwitter

[Liver International @LiverInt]

1/2
A multicenter 🇪🇸 study shows that #Rituximab is a safe & effective option for patients with refractory autoimmune hepatitis

It achieved complete biochemical response in 89% of cases, ⬇️ need for immunosuppressants & corticosteroids

🔓 https://t.co/y3nLAotUgV

#Livertwitter